Summary
The field of cancer immunotherapy has witnessed exciting therapeutic advances in the last decade, but still a large fraction of patients is not responsive and several cancer types are refractory to this therapy. The presence of a strongly immunosuppressive environment is a likely explanation for the suboptimal efficacy of immunotherapy. One of the most abundant and immune suppressive population in the tumor microenvironment (TME) is represented by tumor-associated macrophages (TAMs). Therefore, several strategies that sculpt the TAM phenotype away from their immunosuppressive state are expected to become the next generation immunotherapies.
Supported by the ERC consolidator grant ImmunoFit, we recently unveiled that the metabolic editing of the TME via the pharmacological and genetic inhibition of HPGDS in macrophages (an enzyme involved in the production of prostaglandin D2 from arachidonic acid), represents a novel therapeutic strategy to sculpt TAMs away from their immunosuppressive state, increase infiltration and fitness of CD8+ T cells and NK cells, and promote tumor vessel normalization. This change in the TME upon HPGDS inhibition overcomes resistance to current immunotherapeutic regimens in melanoma and other cancer indications. This proposal aims to de-risk HPGDS targeting by delivering a lead compound with proven efficacy in several preclinical models. The deliverables of this project will open-up a window of opportunities in immune-oncology and lead to novel combination therapies by increasing the potency of the current therapeutic approaches.
Supported by the ERC consolidator grant ImmunoFit, we recently unveiled that the metabolic editing of the TME via the pharmacological and genetic inhibition of HPGDS in macrophages (an enzyme involved in the production of prostaglandin D2 from arachidonic acid), represents a novel therapeutic strategy to sculpt TAMs away from their immunosuppressive state, increase infiltration and fitness of CD8+ T cells and NK cells, and promote tumor vessel normalization. This change in the TME upon HPGDS inhibition overcomes resistance to current immunotherapeutic regimens in melanoma and other cancer indications. This proposal aims to de-risk HPGDS targeting by delivering a lead compound with proven efficacy in several preclinical models. The deliverables of this project will open-up a window of opportunities in immune-oncology and lead to novel combination therapies by increasing the potency of the current therapeutic approaches.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/101123280 |
| Start date: | 01-02-2024 |
| End date: | 31-07-2025 |
| Total budget - Public funding: | - 150 000,00 Euro |
Cordis data
Original description
The field of cancer immunotherapy has witnessed exciting therapeutic advances in the last decade, but still a large fraction of patients is not responsive and several cancer types are refractory to this therapy. The presence of a strongly immunosuppressive environment is a likely explanation for the suboptimal efficacy of immunotherapy. One of the most abundant and immune suppressive population in the tumor microenvironment (TME) is represented by tumor-associated macrophages (TAMs). Therefore, several strategies that sculpt the TAM phenotype away from their immunosuppressive state are expected to become the next generation immunotherapies.Supported by the ERC consolidator grant ImmunoFit, we recently unveiled that the metabolic editing of the TME via the pharmacological and genetic inhibition of HPGDS in macrophages (an enzyme involved in the production of prostaglandin D2 from arachidonic acid), represents a novel therapeutic strategy to sculpt TAMs away from their immunosuppressive state, increase infiltration and fitness of CD8+ T cells and NK cells, and promote tumor vessel normalization. This change in the TME upon HPGDS inhibition overcomes resistance to current immunotherapeutic regimens in melanoma and other cancer indications. This proposal aims to de-risk HPGDS targeting by delivering a lead compound with proven efficacy in several preclinical models. The deliverables of this project will open-up a window of opportunities in immune-oncology and lead to novel combination therapies by increasing the potency of the current therapeutic approaches.
Status
SIGNEDCall topic
ERC-2023-POCUpdate Date
12-03-2024
Images
No images available.
Geographical location(s)
